Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Overview
- Phase
- Not Applicable
- Intervention
- Verteporfin
- Conditions
- Central Serous Chorioretinopathy
- Sponsor
- Helse Stavanger HF
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Change in mean blur rate
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.
Detailed Description
Acute CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics are related to the eventual resolution of subretinal fluid. Such relation can shed light on pathophysiological disease mechanisms and constitute a biomarker for disease activity. Chronic CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics will change in response to standard treatment with PDT. The research of such changes will increase the understanding of the treatment response. This knowledge will help in the effort to understand the why some patients are non-responsive to the treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able to sign informed consent
- •Possible to obtain fundus imaging
- •Acute CSC ˂4 months of duration in one eye, defined as:
- •Subfoveal presence of SRF on OCT
- •Present attack is 1st -3rd attack of CSC
- •b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT
- •Chronic CSC ≥4 months of duration in one eye, defined as:
- •Subfoveal presence of SRF on OCT
- •Subjective visual loss/symptoms
- •Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT
Exclusion Criteria
- •History of retinal disease other than CSC (e.g. retinal detachment)
- •Contraindications for FA, ICGA or PDT (only for chronic CSC)
Arms & Interventions
Chronic
Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months.
Intervention: Verteporfin
Outcomes
Primary Outcomes
Change in mean blur rate
Time Frame: 6 months
Relative changes in choroidal blood flow
Change in pulse wave form analysis
Time Frame: 6 months
Changes in the shapes of pulse curves
Secondary Outcomes
- Change in choroidal density(6 months)
- Change in choroidal thickness(6 months)